Key Points
- Edwards Lifesciences SVP Andrew Dahl sold 544 shares at an average price of $91.06, generating $49,536.64 and reducing his holdings by 3.53% to 14,868 shares.
- The company reported quarterly revenue of $1.74 billion and earnings of $0.78 per share, exceeding analyst estimates, while revenue increased 13.6% year over year.
- Institutional investors own 79.46% of Edwards Lifesciences, and analysts maintain a “Moderate Buy” consensus with an average price target of $100.27.
Edwards Lifesciences Corporation (NYSE:EW - Get Free Report) SVP Andrew Dahl sold 544 shares of the company's stock in a transaction dated Monday, August 31st. The shares were sold at an average price of $91.06, for a total transaction of $49,536.64. Following the transaction, the senior vice president owned 14,868 shares in the company, valued at approximately $1,353,880.08. This trade represents a 3.53% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Edwards Lifesciences Stock Performance
Shares of Edwards Lifesciences stock opened at $90.86 on Tuesday. The company has a 50 day moving average price of $89.64 and a 200 day moving average price of $85.18. The firm has a market capitalization of $52.32 billion, a P/E ratio of 52.22, a PEG ratio of 2.37 and a beta of 0.85. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 52 week low of $72.30 and a 52 week high of $96.29.
Edwards Lifesciences (NYSE:EW - Get Free Report) last released its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The company had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.70 billion. During the same quarter in the previous year, the firm earned $0.67 EPS. Edwards Lifesciences's revenue was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Sell-side analysts expect that Edwards Lifesciences Corporation will post 3 EPS for the current year.
Institutional Investors Weigh In On Edwards Lifesciences
Several hedge funds and other institutional investors have recently added to or reduced their stakes in EW. California State Teachers Retirement System lifted its holdings in shares of Edwards Lifesciences by 9,187.8% in the 2nd quarter. California State Teachers Retirement System now owns 80,962,062 shares of the medical research company's stock valued at $7,323,828,000 after buying an additional 80,090,362 shares during the period. BlackRock Inc. acquired a new stake in Edwards Lifesciences during the second quarter worth about $5,318,092,000. State Street Corp raised its position in Edwards Lifesciences by 1.5% during the fourth quarter. State Street Corp now owns 25,991,524 shares of the medical research company's stock valued at $2,215,777,000 after acquiring an additional 371,892 shares in the last quarter. Wellington Management Group LLP raised its position in Edwards Lifesciences by 4.8% during the fourth quarter. Wellington Management Group LLP now owns 21,793,949 shares of the medical research company's stock valued at $1,857,934,000 after acquiring an additional 989,533 shares in the last quarter. Finally, Bank of New York Mellon Corp purchased a new position in Edwards Lifesciences during the second quarter valued at approximately $1,274,082,000. 79.46% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
A number of equities analysts recently issued reports on EW shares. Citigroup raised their target price on Edwards Lifesciences from $101.00 to $110.00 and gave the stock a "buy" rating in a research note on Wednesday, July 8th. Evercore reiterated an "outperform" rating and set a $100.00 price target on shares of Edwards Lifesciences in a research note on Monday, July 6th. Weiss Ratings reissued a "hold (c)" rating on shares of Edwards Lifesciences in a report on Friday, July 17th. Leerink Partners upgraded Edwards Lifesciences from a "market perform" rating to an "outperform" rating and raised their price objective for the stock from $87.00 to $101.00 in a research note on Friday, July 24th. Finally, JPMorgan Chase & Co. lifted their target price on Edwards Lifesciences from $100.00 to $105.00 and gave the stock an "overweight" rating in a report on Friday, July 24th. Seventeen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $100.27.
View Our Latest Stock Analysis on Edwards Lifesciences
About Edwards Lifesciences
(
Get Free Report)
Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.
In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
